Phibro Animal Health (NASDAQ:PAHC) Upgraded at StockNews.com

StockNews.com upgraded shares of Phibro Animal Health (NASDAQ:PAHC - Free Report) from a buy rating to a strong-buy rating in a research report released on Saturday morning.

A number of other analysts also recently weighed in on PAHC. Morgan Stanley upped their target price on shares of Phibro Animal Health from $20.00 to $25.00 and gave the stock an "equal weight" rating in a research report on Tuesday, December 17th. JPMorgan Chase & Co. initiated coverage on shares of Phibro Animal Health in a report on Tuesday, September 10th. They set a "neutral" rating and a $22.00 target price for the company. Finally, Barclays boosted their price target on Phibro Animal Health from $13.00 to $20.00 and gave the stock an "underweight" rating in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $20.50.

Phibro Animal Health Stock Down 1.0 %

Shares of PAHC traded down $0.21 on Friday, reaching $20.52. The stock had a trading volume of 100,725 shares, compared to its average volume of 110,412. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.69 and a current ratio of 3.23. Phibro Animal Health has a 12-month low of $10.03 and a 12-month high of $25.98. The firm has a market capitalization of $831.12 million, a price-to-earnings ratio of 47.72, a price-to-earnings-growth ratio of 0.58 and a beta of 0.53. The company has a 50-day simple moving average of $23.01 and a 200-day simple moving average of $20.96.

Phibro Animal Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th were issued a $0.12 dividend. The ex-dividend date was Wednesday, November 27th. This represents a $0.48 annualized dividend and a yield of 2.34%. Phibro Animal Health's dividend payout ratio (DPR) is presently 111.63%.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in Phibro Animal Health by 5.7% in the 3rd quarter. Geode Capital Management LLC now owns 507,469 shares of the company's stock valued at $11,430,000 after acquiring an additional 27,201 shares in the last quarter. Barclays PLC raised its stake in shares of Phibro Animal Health by 25.7% in the third quarter. Barclays PLC now owns 143,337 shares of the company's stock worth $3,228,000 after purchasing an additional 29,271 shares during the last quarter. Zacks Investment Management bought a new position in shares of Phibro Animal Health during the third quarter valued at $274,000. Virtus Investment Advisers Inc. boosted its position in shares of Phibro Animal Health by 65.1% during the third quarter. Virtus Investment Advisers Inc. now owns 24,344 shares of the company's stock valued at $548,000 after buying an additional 9,600 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Phibro Animal Health by 116.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company's stock worth $4,330,000 after buying an additional 103,491 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.